Aurobindo Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 785.95, up 1.42% on the day as on 12:54 IST on the NSE. The benchmark NIFTY is up around 0.6% on the day, quoting at 10107.25. The Sensex is at 34213.19, up 0.76%. Aurobindo Pharma Ltd has risen around 18.28% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 9.01% in last one month and is currently quoting at 10122.05, up 0.23% on the day. The volume in the stock stood at 34.41 lakh shares today, compared to the daily average of 66.91 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 785.55, up 1.42% on the day. Aurobindo Pharma Ltd is up 20.51% in last one year as compared to a 15.53% drop in NIFTY and a 23.08% drop in the Nifty Pharma index.

The PE of the stock is 24.26 based on TTM earnings ending March 20.

Powered by Capital Market - Live News

Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 760.25, up 1.31% on the day as on 12:54 IST on the NSE. The benchmark NIFTY is down around 0.99% on the day, quoting at 9962.05. The Sensex is at 33797.72, down 0.91%. Aurobindo Pharma Ltd has risen around 20.37% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 8.53% in last one month and is currently quoting at 9864.05, up 1.02% on the day. The volume in the stock stood at 148.86 lakh shares today, compared to the daily average of 61.95 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 765.05, up 1.57% on the day. Aurobindo Pharma Ltd is up 21.73% in last one year as compared to a 15.89% drop in NIFTY and a 20.36% drop in the Nifty Pharma index.

The PE of the stock is 27.36 based on TTM earnings ending December 19.

Powered by Capital Market - Live News

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected AuroLife Pharma LLC's oral solid manufacturing facility situated at Dayton, New Jersey, a wholly owned step-down subsidiary of the Company, from 13 January to 12 February 2020. At the end of the inspection, a 'Form 483' has been issued with 9 observations. With respect to the mentioned inspection, we have received a letter from USFDA classifying the inspection as “Official Action Indicated.

The Company believes that this OAI classification may not have any material impact on the existing revenues, the supplies of our US business or pipeline products at this juncture. The exclusive sales from this facility is around 2% of the group turnover. The Company will work closely with the regulator to comprehensively address the issues.

Powered by Capital Market - Live News

Consolidated profit before tax stood at Rs 1077.51 crore in Q4 March 2020, rising 32% from Rs 816.34 crore in Q4 March 2019. Total tax expenses declined 1.12% to Rs 228.52 crore in Q4 March 2020 over Q4 March 2019. The company reported deferred tax credit of Rs 101.03 crore in Q4 March 2020, which aided net profit.

Consolidated EBITDA surged 26.6% to Rs 1342 in Q4 March 2020 from Rs 1060 crore in Q4 March 2019. EBITDA margin improved to 21.8% in Q4 March 2020 from 20% in Q4 March 2019.

Research & Development expenses for Q4 March 2020 stood at Rs 239 crore, 3.9% of revenue.

US formulation sales stood at Rs 2,990.3 crore in Q4 March 2020, registering a growth of 20.5% from Rs 2,481.1 crore in Q4 May 2019. Europe formulation sales stood at Rs 1,652.5 crore, an increase of 26% from the same period last year. API sales for the quarter declined 17.6% and stood at Rs 755.6 crore in Q4 March 2020 as against Rs 916.8 crore in Q4 March 2019.

The pharmaceutical company reduced its net debt to Rs 2718.4 crore in March 2020 from Rs 3181.9 crore in December 2019 and Rs 5008.1 crore in March 2019.

Commenting on the company's performance, N. Govindarajan, managing director of the company said: The new fiscal year has begun with lot of challenges that the globe and industry had never witnessed. We are committed in protecting the health and wellbeing of our employees, their families and other stakeholders. We have closed FY20 with a healthy performance in Q4. The growth was seen across all our geographies. Diversified product basket has helped us to maintain the growth momentum in our core geographies like USA and Europe. We remain focused on strengthening our existing businesses, developing a differentiated & specialty product basket and regulatory compliance.

On a consolidated basis, net profit rose 20% to Rs 2829.51 crore on 18.3% rise in net sales to Rs 22737.95 crore in fiscal year 2020 over fiscal year 2019.

Aurobindo Pharma is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics.

Powered by Capital Market - Live News